title: [Duration of filgrastim prophylaxis for chemotherapy-induced neutropenia and its predictors].
abstract: OBJECTIVE
  To analyze the duration of preventive filgrastim administration as support for chemotherapy and its affecting factors.
  
  
  METHODS
  Single institutional data from a phase Ⅱ clinical trial and a phase Ⅲ clinical trial of pegylated filgrastim were combined. In the two randomized cross-over trials, patients with previously untreated cancer received two cycles of chemotherapy of the same regimen. In the study group, the patients received a single subcutaneous injection of 100 μg/kg pegylated filgrastim, and in the control group, they received daily subcutaneous injections of 5 μg/kg filgrastim.
  
  
  RESULTS
  In 53 chemotherapy cycles, the median duration of filgrastim administration was (9.57±2.10)d. 83.0% (44/53) of them received filgrastim for 7-11 days. Patients with baseline absolute neutrophil count of <4×10(9)/L or body mass index less than 22 received a longer filgrastim prophylaxis(P<0.05). RESULTS of multivariate analysis showed that the baseline absolute neutrophil count is associated with the time of filgrastim administration(P=0.019). The most common adverse event of rhG-CSF was skeletal pain, generally mild and no treatment-related death occurred.
  
  
  CONCLUSIONS
  The median duration of filgrastim support for chemotherapy was 10 days. Patients with lower baseline neutrophil count require a longer filgrastim prophylaxis.
  
  
  BACKGROUND
  : ClinicalTrials.gov identifier, NCT01285219.
authors.affiliation: Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Yang
authors.forename: Xiaohui
authors.initials: X
authors.lastname: He
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Shengyu
authors.initials: S
authors.lastname: Zhou
authors.forename: Mei
authors.initials: M
authors.lastname: Dong
authors.forename: Yan
authors.initials: Y
authors.lastname: Qin
authors.forename: Jianliang
authors.initials: J
authors.lastname: Yang
authors.forename: Changgong
authors.initials: C
authors.lastname: Zhang
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Han
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D018592:Cross-Over Studies; D000069585:Filgrastim / Q000009:adverse effects / Q000627:therapeutic use*; D006401:Hematologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D060828:Induction Chemotherapy; D007279:Injections, Subcutaneous; D015999:Multivariate Analysis; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D006401:Hematologic Agents; D000069585:Filgrastim